Business & Markets
EU clears Kimberly-Clark’s Kenvue deal with feminine-care divestiture
The remedy transfers Kimberly-Clark’s tampon and other feminine-hygiene brands, related intellectual property and key staff to an approved buyer. The acquisition itself has not closed.
Executive summary
- The approval comes with a broad brand sale: The European Commission approved Kimberly-Clark’s proposed acquisition of consumer-health company Kenvue on Oct. 13, conditional on full compliance with commitments to divest Kimberly-Clark’s tampon and other feminine-hygiene brands across the European Economic Area.[1][2]
- Kotex and related assets are part of the remedy: The divestiture covers Kotex, including the Lidie sub-brand, Camelia and Record, along with intellectual property, know-how, key employees and business relationships. The Commission approved Turkey-based Dilek as purchaser and said an independent trustee will monitor implementation.[1][2]
- The acquisition remains pending: The EU decision addresses the regulator’s competition concerns; it does not mean the merger has closed. Kimberly-Clark’s Oct. 13 SEC filing said it expected the acquisition to close in the fourth quarter of 2026, subject to the remaining conditions.[1][3]
The European Commission approved Kimberly-Clark’s proposed acquisition of Kenvue under the EU Merger Regulation on Oct. 13, but made its decision conditional on full compliance with commitments offered by Kimberly-Clark. The Commission’s press release describes the proposal as an acquisition and says the conditions must be implemented; the regulatory decision is not a report that the companies have combined.[1][2]
Kimberly-Clark’s filing with the U.S. Securities and Exchange Commission that day continued to describe the transaction as pending and said the company expected it to close in the fourth quarter of 2026. The timetable remains an expectation, not a completed closing or guarantee.[3]
The Commission said it was concerned that the deal as originally notified would reduce competition in tampon markets, particularly in Czechia, Estonia and Slovakia, where it found few other suppliers. Its remedy requires the sale across the European Economic Area of Kimberly-Clark’s tampon and other feminine-hygiene brands, including Kotex (and its Lidie sub-brand), Camelia and Record.[1][2][4]
The commitment extends beyond brand names: it includes related intellectual-property rights, know-how, key employees and business relationships. The Commission also approved Dilek Gıda Üretim ve Pazarlama Ticaret A.Ş., a Turkey-based consumer-goods distributor, as the purchaser. An independent trustee will supervise implementation on the Commission’s behalf.[1][2]
The Commission said it considered the divestiture sufficient to remove the overlap between the companies’ activities in the European Economic Area. The sale is therefore a central condition of clearance, rather than a post-closing remedy left for the combined company to resolve later.[1]
The proposed acquisition brings Kimberly-Clark’s consumer-products business together with Kenvue’s health brands. The EU review focused on a narrower issue: whether combining their feminine-care offerings would remove an important supplier in several national tampon markets. Divesting Kimberly-Clark’s European feminine-hygiene portfolio is intended to preserve a separate competitor while allowing the broader acquisition to proceed, provided the commitments are fully carried out.[1][4]
Reuters and Europa Press independently reported the conditional approval and the brand sale. The Commission’s own decision summary supplies the basis for the remedy and its competition rationale. The public case record and future implementation will show how the sale is completed; the clearance alone does not establish that the business has already transferred or that the acquisition has closed.[1][2][4][3]